TABLE 11.

Clinical trials of SRT2379 and SRT3025.

Condition	Phase	Subjects	Dose	Outcome	References
Type 2 diabetes	I	64	25–3,000 mg SRT2379	SRT2379 exposure increased in a dose-dependent manner	NCT01018628, GSK Study Register
Inflammation	I	17	1,000 mg SRT2379	SRT2379 treatment had a trend of anti-inflammatory effects, but was not statistically significant	NCT01262911, GSK Study Register
Inflammation	I	39	50–1,000 mg SRT2379	SRT2379 treatment did have a significant anti-inflammatory effect	Wiewel et al., 2013
Type 2 diabetes	I	78	50–3,000 mg SRT3025	SRT3025 treatment stopped due to potential adverse cardiovascular side effects	NCT01340911, GSK Study Register